VEGFC
EmergingVEGF-C drives lymphangiogenesis and is studied as a research marker for lymph node metastasis risk in cancer.
VEGF-C helps tumors build new lymphatic vessels, which can give cancer cells extra pathways to spread to lymph nodes. It's an active area of cancer research, though not yet a standard clinical test.
Vascular endothelial growth factor C (VEGF-C) drives lymphangiogenesis (new lymphatic vessel formation), distinct from VEGF-A's role in blood vessel formation targeted by more familiar anti-angiogenic cancer drugs.
Elevated tumor VEGF-C is associated with lymph node metastasis risk across several cancer types, since new lymphatic vessels can provide additional routes for tumor cells to spread to lymph nodes.
Measured via tissue immunohistochemistry or research-grade serum assay; VEGF-C is not yet a standardized clinical diagnostic test, functioning primarily as a research biomarker for metastatic risk assessment.
VEGF-C is being studied as a biomarker for response to anti-angiogenic and anti-lymphangiogenic therapies, an active area of oncology drug development, though no VEGF-C-specific therapy is yet in routine clinical use.
An active area of anti-lymphangiogenic drug development research, not yet a standardized clinical test.
- General oncology reference literature on VEGF-C in lymphangiogenesis and lymph node metastasis research.